Trial Profile

A Pilot Study of Loncastuximab Tesirine in Specific Populations of Relapsed/Refractory B-Cell Malignancies

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Loncastuximab tesirine (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Post-transplant lymphoproliferative disorder
Focus Therapeutic Use

Most Recent Events

16 Apr 2025 Planned End Date changed from 6 Jul 2026 to 6 Jul 2027.
16 Apr 2025 Planned primary completion date changed from 15 Dec 2025 to 15 Dec 2026.
22 Jun 2023 Planned initiation date (estimated date of first participant enrollment) changed from 30 Apr 2023 to 22 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com